Cancel

Ace the Case: 61-Year-Old Male Who Presents to the ER with Worsening Back Pain

This “Ace the Case” activity will review the diagnosis and management of patients with high-risk multiple myeloma utilizing a case-based approach.
Slack Inc.

Multiple Myeloma Expert Roundtable: Stem Cell Transplantation, Maintenance Therapy, and Relapsed/Refractory Disease

With numerous recent advances in available treatments and options for diagnosis and staging, disease monitoring, and supportive care, the outlook for patients with multiple myeloma has never been brighter. However, this expansion of clinical options has also introduced potentially daunting challenges for the health care providers charged with the care of these patients. This activity presents a robust roundtable discussion in which our expert faculty provides insights on such issues as dete...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Multiple Myeloma Expert Roundtable: Risk Assessment, Minimal Residual Disease, and Precision Medicine

The clinical multiple myeloma arena has undergone significant advancement in recent years; not only have 10 drugs been added to the armamentarium, but there have been important developments in diagnosis and staging, minimal residual disease (MRD) monitoring, and supportive care. The expansion of clinical options brings both opportunities and challenges for health care providers who see myeloma patients. In this roundtable, our expert panel discusses the newest evidence regarding the identif...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Clinical Perspectives in Oncology Nursing: Management and Treatment of Multiple Myeloma

medications for the treatment of MM, a new burden is placed upon clinicians who care for these patients to become educated on these novel drugs’ benefits and side effects profiles and to integrate them into clinical practice. It is crucial to achieving optimum outcomes for patients with MM that they are offered access to the latest innovations in treatment. However, for this to happen, the entire care team—including oncology nurses and advanced practice nurses—need to be fully apprised o...
American Academy of CME

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit. Le...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Navigating New Options to Improve Outcomes in Multiple Myeloma

As new combinations and classes of agents emerge for the treatment of multiple myeloma (MM), community-based treatment teams require clarity on the optimal integration of recently approved and emerging agents into the relapsed/refractory landscape for MM. While high-dose chemotherapy is not appropriate for all patients, multiple options have emerged that demonstrate a clinical benefit and require proper integration into the treatment paradigm. In addition, clinicians must meet requirements for...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

New Drugs Approved in 2015

In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 new molecular entities – the highest annual number of new drugs to be approved in the past decade (up from 41 in 2014). The new approvals include 16 first-in-class drugs spanning 14 different medical conditions. Many of the new drugs were approved under one or more of the FDA’s 4 expedited pathways (fast track, breakthrough, priority review, and accelerated approval). Nearly half are for the treatment of rare d...
The Rx Consultant

The Brigham Board Review in Hematology and Oncology

Get ready for the ABIM exam in Hematology-Oncology by studying this Brigham Board Review in Hematology and Oncology. Topics covered by the Brigham Board Review in Hematology and Oncology include: Molecular Genetics of Cancer, Cancer Drug Development, Hematopoietic Stem Cell Transplantation, Acute Leukemias, Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, B Cell Malignancies, Mesothelioma, Thyroid Cancer and dozens of others. After completing the Brigham Board Review in Hemat...
CMEInfo

Osler Radiation Oncology Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Osler Surgery MOC Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.